Consistent with the goals ofthe Rare Diseases Clinical Research Network (RDCRN), the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) Clinical Research Projects for Observational/Longitudinal Studies or Clinical Trials have been developed in joint partnership with patient advocacy groups (PAGs) with the objective of answering immediately important questions concerning the rare diseases eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), and eosinophilic colitis (EC).
We aim to 1) better define the diagnostic and clinical features of these diseases (Project 1);2) determine whether the level of tissue eosinophils, a parameter that is currently required for disease diagnosis, is an adequate measurement of clinical outcome as it has so far been assumed that the level reflects disease severity and adverse prognosis (Project 1);3) develop validated clinical outcome metrics (COMs) that can be used to quantitatively monitor disease (Project 1);4) identify and refine biomarkers on the basis of novel approaches that take advantage of direct procurement of readily accessible diseased tissue that will be subjected to whole-genome transcriptome profiling (Project 1 and Project 2);5) conduct a clinical trial that optimizes therapy for the most common of these diseases (EoE) on the basis of currently available approaches - dietary elimination diets and glucocorticoids (Project 2);and 6) develop a personalized and predictive medicine approach to understanding and treating these diseases (Project 1 and Project 2).

Public Health Relevance

The proposed clinical research projects have been developed in partnership with patient advocacy groups with the objective of answering immediately important questions concerning the understanding and treatment ofthe rare diseases eosinophilic esophagitis, eosinophilic gastritis, and eosinophilic colitis. These diseases are painful, lifelong diseases that make it difficult or impossible for individuals to eat many or all foods.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZTR1-CI-8 (01))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Cincinnati Children's Hospital Medical Center
United States
Zip Code
Naramore, Sara; Gupta, Sandeep K (2018) Nonesophageal Eosinophilic Gastrointestinal Disorders: Clinical Care and Future Directions. J Pediatr Gastroenterol Nutr 67:318-321
Steinbach, Erin C; Hernandez, Michelle; Dellon, Evan S (2018) Eosinophilic Esophagitis and the Eosinophilic Gastrointestinal Diseases: Approach to Diagnosis and Management. J Allergy Clin Immunol Pract 6:1483-1495
Spergel, Jonathan; Aceves, Seema S (2018) Allergic components of eosinophilic esophagitis. J Allergy Clin Immunol 142:1-8
Hill, David A; Spergel, Jonathan M (2018) Is eosinophilic esophagitis a member of the atopic march? Ann Allergy Asthma Immunol 120:113-114
Spergel, Jonathan M; Dellon, Evan S; Liacouras, Chris A et al. (2018) Summary of the updated international consensus diagnostic criteria for eosinophilic esophagitis: AGREE conference. Ann Allergy Asthma Immunol 121:281-284
Wechsler, Joshua B; Hirano, Ikuo (2018) Biological therapies for eosinophilic gastrointestinal diseases. J Allergy Clin Immunol 142:24-31.e2
O'Shea, Kelly M; Aceves, Seema S; Dellon, Evan S et al. (2018) Pathophysiology of Eosinophilic Esophagitis. Gastroenterology 154:333-345
Shoda, Tetsuo; Wen, Ting; Aceves, Seema S et al. (2018) Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. Lancet Gastroenterol Hepatol 3:477-488
Wang, Ryan; Hirano, Ikuo; Doerfler, Bethany et al. (2018) Assessing Adherence and Barriers to Long-Term Elimination Diet Therapy in Adults with Eosinophilic Esophagitis. Dig Dis Sci 63:1756-1762
Hill, David A; Spergel, Jonathan M (2018) The atopic march: Critical evidence and clinical relevance. Ann Allergy Asthma Immunol 120:131-137

Showing the most recent 10 out of 103 publications